> News > Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting
13.12
2021

Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting


  • ISB 1442 is a First-In-Class 2+1 Biparatopic Bispecific BEAT® 2.0 Antibody Targeting CD38 and CD47

  • Data from Preclinical Models Suggest Higher Potency and Tumor Growth Inhibition for ISB 1442 Relative to Daratumumab

  • Enrollment in the First-in-Human ISB 1442 Trial is Expected to Start in Mid-2022


NEW YORK, NY, December 11, 2021 – Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support the potential for ISB 1442, a first-in-class 2+1 biparatopic bispecific antibody that targets both CD38 and CD47, as a treatment for relapsed/refractory multiple myeloma and other CD38+ hematological malignancies. The data were presented today by Stefano Sammicheli, Ph.D., Director of Innate Cell Engagers, during an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting.

More information

Company related to the news